扫描下面的二维码:

二维码

学术文章

[APASL前沿]肝纤维化治疗探索:基因治疗、细胞治疗2020-04-01

肝癌诊疗新工具ARCHTECT PIVKA-II2020-04-01

[APASL前沿]TACE治疗HCC的规范化实践地区差异明显2020-04-01

[APASL热点]大会报告:失代偿期丙型肝炎肝硬化患者全口服抗病毒治疗获益2020-04-01

New Endpoints in HBV Drug Development2020-04-01

Portal Vein Thrombosis in Cirrhotic and Non-cirrhotic Liver2020-04-01

Hepatology Keeps Moving into the Future2020-04-01

New Drugs to Overwhelm the Barriers to Eliminate HCV2020-04-01

Welcome Message——Jinlin Hou2020-04-01

AARC-ACLF, the Better Prognostic Score—AARC-ACLF Score predicts 30-day survival better than CLIF-SOFA2020-04-01

LDV/SOF Efficacious in HCV Patients with Decompensated Cirrhosis2020-04-01

VEL/SOF Effective in HCV Patients with Decompensated Cirrhosis2020-04-01

TDF Effective in HBV Long-term Treatment2020-04-01

Radiofrequency Ablation (RFA) Know-How in 2 Days — Juntendo University radiofrequency ablation (RFA) training program2020-04-01

REP2139-Ca, a Promising NAP to Treat HBV2020-04-01

At 38 years, just Young and Robust—25th APASL Opening Ceremony2020-04-01

For HBV/HCV Co-infection Patients in DAA Era, Treat the Viruses both!2020-04-01

Hepatitis B Treatment: Yesterday, Today and Tomorrow2020-04-01

The Situation of Liver Diseases in Asian-Pacific countries and the Urgent Tasks for Beating HCV and HBV2020-04-01

[APASL前沿]姜黄素可以改善肝硬化大鼠的门静脉高压症 2020-04-01



设为首页 | 加入收藏 | 网站地图 | 订阅杂志 | 关于我们 | 版权声明 | 联系方式|招贤纳士
国际肝病  版权所有  京ICP备15060708号   (京)-非经营性-2016-0001京公网安备 11010502033341号 2004-2020  www.ihepa.com  ALL Rights  Reserved

增值电信业务经营许可证:京B2-20212326

网站统计